Feb 01, 2018 10:00 AM


nicola camp and rosalie waller

Study uses human pedigrees to find genetic causes of complex diseases like myeloma

SALT LAKE CITY –  Researchers have identified two gene regions that contribute to multiple myeloma, an inherited cancer that occurs in bone marrow, through a new method that makes use of human disease pedigrees. Nicola Camp and Rosalie Waller of Huntsman Cancer Institute at the University of Utah and colleagues report their findings February 1st in PLOS Genetics

Human pedigrees can help geneticists to track diseases through different branches of a family tree and pinpoint the mutations that are responsible. This process is straightforward in diseases caused by a mutation in a single gene, but for complex diseases, which involve multiple genes, the use of pedigrees has not been so effective. In the current study, researchers developed a new method to analyze high-risk pedigrees (large, multi-generational families with more affected members than would be expected by chance) to identify shared regions of the genome that likely harbor disease-causing genes. They applied the method using pedigrees from 11 Utah families at risk of multiple myeloma, a complex, heritable cancer that causes malignant immune cells to proliferate in the bone marrow. The analysis revealed two regions that may contribute to the disease: one involved in regulating DNA repair, and the other, a key gene involved in packaging DNA inside the cell’s nucleus.

The myeloma findings from the new study demonstrate that high-risk pedigrees, a classic design for straightforward diseases, can also be successful for pinning down genes that contribute to complex diseases with appropriate analytics. This new strategy may be helpful for narrowing in on the genetic causes underlying other common yet complex diseases, such as obesity, diabetes and Alzheimer’s disease.

Nicola Camp adds: “We are very encouraged by the new method. It certainly plays to the strengths of the large Utah pedigrees, revitalizing the family design for complex diseases. As we did in this study, the focused regions can be further investigated in smaller families to find genes and specific mutations. The method can be used for any complex disease. We are already pursuing large pedigrees in several other domains, including other cancers, psychiatric disorders, birth defects, and pre-term birth phenotypes, with several more genome-wide significant regions found. We’re excited about the potential.”

Research reported in this publication was supported by funding from the Utah Genome Project; Huntsman Cancer Institute Hematology Disease Oriented Team; Leukemia and Lymphoma Society; National Institutes of Health (NIH) grant numbers: R01-CA-107476, R01-CA-134674, R21-CA-152336, R01-CA-163353, R01-CA-167824, R01-CA-168762, R21-CA-191896, R01-DK-091374, R01-DK-093151, R01-MH-094400, R01-MH-099134, S10-OD-018522, and T15-LM-007124. Partial support for all datasets within the Utah Population Data Base is provided by the Huntsman Cancer Institute (HCI), and the HCI Cancer Center Support grant, P30-CA-42014 from the NIH. The Utah Cancer Registry is funded by the National Cancer Institute's SEER Program, Contract No. HHSN261201300017I, with additional support from the Utah Department of Health and the University of Utah. The research reported in this publication was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001067 and the Huntsman Cancer Foundation. The authors declare no conflict of interest.

Media Contact

Ashlee Harrison
Public Relations – Huntsman Cancer Institute
public.affairs@hci.utah.edu
801-585-1954

Cancer Center Research Program Cancer Control and Population Sciences

About Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute (HCI) at the University of Utah is the official cancer center of Utah and the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West. The campus includes a state-of-the-art cancer specialty hospital, and two buildings dedicated to cancer research. HCI provides patient care, cancer screening, and education at community clinics and affiliate hospitals throughout the Mountain West. HCI is consistently recognized among the best cancer hospitals in the country by U.S. News and World Report. The region’s first proton therapy center opened in 2021 and a major hospital expansion is underway. HCI is committed to creating a diverse and inclusive environment for staff, students, patients, and communities. Advancing cancer research discoveries and treatments to meet the needs of patients who live far away from a major medical center is a unique focus. More genes for inherited cancers have been discovered at HCI than at any other cancer center, including genes responsible for breast, ovarian, colon, head and neck cancers, and melanoma. HCI was founded by Jon M. and Karen Huntsman.

Cancer touches all of us.

Share Your Story